CoChat

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis

Open access

Abstract

BACKGROUND: Previous animal studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1RAs) suppress arterial restenosis, a major complication of angioplasty, presumably through their direct action on vascular smooth muscle cells. However, the contribution of vascular endothelial cells (VECs) to this process remains unknown. In addition, the potential interference caused by severe hyperglycemia and optimal treatment regimen remain to be determined. METHODS: Nine-week-old male C57BL6 (wild-type) and diabetic db/db mice were randomly divided into vehicle or liraglutide treatment groups (Day 1), and subject to femoral artery wire injuries (Day 3). The injured arteries were collected on Day 29 for morphometric analysis. Human umbilical vein endothelial cells (HUVECs) were used for in vitro experiments. One-way ANOVA, followed by Tukey's test, was used for comparisons. RESULTS: In wild-type mice, liraglutide treatment (5.7, 17, or 107 nmol/kg/day) dose-dependently reduced the neointimal area (20, 50, and 65%) without inducing systemic effects, and caused an associated decrease in the percentage of vascular proliferating cells. However, these effects were completely abolished by the nitric oxide synthase (NOS) inhibitor N-omega-nitro-L-arginine methyl ester. Next, we investigated the optimal treatment regimen. Early treatment (Days 1-14) was as effective in reducing the neointimal area and vascular cell proliferation as full treatment (Days 1-29), whereas delayed treatment (Days 15-29) was ineffective. In HUVECs, liraglutide treatment dose-dependently stimulated NO production, which was dependent on GLP-1R, cAMP, cAMP-dependent protein kinase, AMP-activated protein kinase (AMPK), and NOS. Subsequently, we investigated the role of liver kinase B (LKB)-1 in this process. Liraglutide increased the phosphorylation of LKB-1, and siRNA-induced LKB-1 knockdown abolished liraglutide-stimulated NO production. In severe hyperglycemic db/db mice, liraglutide treatment also suppressed neointimal hyperplasia, which was accompanied by reductions in vascular cell proliferation and density. Furthermore, liraglutide treatment suppressed hyperglycemia-enhanced vascular inflammation 7 days after arterial injury. CONCLUSIONS: We demonstrate that endothelial cells are targets of liraglutide, and suppress restenosis via endothelial NO. Furthermore, the protective effects are maintained in severe hyperglycemia. Our findings provide an evidence base for a future clinical trial to determine whether treatment with GLP-1RAs represents potentially effective pharmacological therapy following angioplasty in patients with diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-017-0603-x

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Design of animal experiments (1–5). The liraglutide dose was 17 nmol/kg/day, unless otherwise specified. N-omega-nitro-l-arginine methyl ester (l-NAME) was administered via drinking water at the dose of 20 mg/kg/day; LFA, left femoral artery
Fig. 1 Design of animal experiments (1–5). The liraglutide dose was 17 nmol/kg/day, unless otherwise specified. N-omega-nitro-l-arginine methyl ester (l-NAME) was administered via drinking water at the dose of 20 mg/kg/day; LFA, left femoral arteryCC BY · PubMed Central
Fig. 2 Liraglutide dose-dependently suppresses neointimal hyperplasia. Wild-type mice treated with vehicle or liraglutide at different doses were subject to femoral artery wire injury. The arteries were collected for morphometric analysis 26 days after injury. Cell density was calculated as the number of total cells divided by the area; a representative images of cross-sections of femoral arteries; Elastica van Gieson (EVG) staining, 200 ×; b neointimal area; c medial area; d arterial perimeter; e intima to media (I/M) ratio. The averages of three serial cross-sections were used as single data points. Arrows indicate the neointima; vehicle and liraglutide at 5.7 and 107 nmol/kg/day, n = 5; liraglutide at 17 nmol/kg/day, n = 6; *p < 0.05; **p < 0.01
Fig. 2 Liraglutide dose-dependently suppresses neointimal hyperplasia. Wild-type mice treated with vehicle or liraglutide at different doses were subject to femoral artery wire injury. The arteries were collected for morphometric analysis 26 days after injury. Cell density was calculated as the number of total cells divided by the area; a representative images of cross-sections of femoral arteries; Elastica van Gieson (EVG) staining, 200 ×; b neointimal area; c medial area; d arterial perimeter; e intima to media (I/M) ratio. The averages of three serial cross-sections were used as single data points. Arrows indicate the neointima; vehicle and liraglutide at 5.7 and 107 nmol/kg/day, n = 5; liraglutide at 17 nmol/kg/day, n = 6; *p < 0.05; **p < 0.01CC BY · PubMed Central
Fig. 3 The anti-restenotic effects of liraglutide are mediated by nitric oxide (NO). Wild-type mice were treated with vehicle or liraglutide, with or without the NO synthase (NOS) inhibitor l-NAME. Femoral arteries were collected 26 days after arterial injury. Morphometric changes were evaluated by EVG staining. Cell proliferation and density were assessed by Ki-67 immunostaining and counterstaining. Proliferating cells were defined as cells positive for Ki-67; a representative images of cross-sections of femoral arteries (EVG, 200 ×); b neointimal area; c medial area; d, arterial perimeter; e intima to media (I/M) ratio; f representative images of injured arteries showing Ki-67 immunostaining (200 ×); g, h percentage of Ki-67-positive cells to total cells in the neointima and media; i, j, cell density in the neointima and media. The averages of three serial cross-sections were used as single data points. Arrows indicate the neointima, and arrowheads indicate Ki-67-positive cells; liraglutide, 17 nmol/kg/day; l-NAME, 20 mg/kg/day; n = 5 per group; *p < 0.05
Fig. 3 The anti-restenotic effects of liraglutide are mediated by nitric oxide (NO). Wild-type mice were treated with vehicle or liraglutide, with or without the NO synthase (NOS) inhibitor l-NAME. Femoral arteries were collected 26 days after arterial injury. Morphometric changes were evaluated by EVG staining. Cell proliferation and density were assessed by Ki-67 immunostaining and counterstaining. Proliferating cells were defined as cells positive for Ki-67; a representative images of cross-sections of femoral arteries (EVG, 200 ×); b neointimal area; c medial area; d, arterial perimeter; e intima to media (I/M) ratio; f representative images of injured arteries showing Ki-67 immunostaining (200 ×); g, h percentage of Ki-67-positive cells to total cells in the neointima and media; i, j, cell density in the neointima and media. The averages of three serial cross-sections were used as single data points. Arrows indicate the neointima, and arrowheads indicate Ki-67-positive cells; liraglutide, 17 nmol/kg/day; l-NAME, 20 mg/kg/day; n = 5 per group; *p < 0.05CC BY · PubMed Central
Fig. 4 Early short, but not delayed, treatment with liraglutide is effective in suppressing restenosis. Liraglutide (17 nmol/kg/day) was administered to mice at different initiation times and durations: Days 1–29 (full), Days 1–14 (Early), and Days 15–29 (Delayed). Changes in morphometry and cell proliferation were evaluated on Day 29; a scheme of the experimental design; b representative images of cross-sections of femoral arteries (EVG, 200 ×); c neointimal area; d medial area; e arterial perimeter; f intima to media (I/M) ratio; g representative images of injured arteries showing Ki-67 immunostaining (200 ×); h, i percentage of Ki-67-positive cells to total cells in the neointima and media, respectively. The averages of three serial cross-sections were used as single data points. Arrows indicate the neointima, and arrowheads indicate Ki-67-positive cells; d–f: n = 6 for vehicle and full treatment; n = 9 for early short treatment; n = 8 for delayed treatment; i, j: n = 5 per group; *p < 0.05
Fig. 4 Early short, but not delayed, treatment with liraglutide is effective in suppressing restenosis. Liraglutide (17 nmol/kg/day) was administered to mice at different initiation times and durations: Days 1–29 (full), Days 1–14 (Early), and Days 15–29 (Delayed). Changes in morphometry and cell proliferation were evaluated on Day 29; a scheme of the experimental design; b representative images of cross-sections of femoral arteries (EVG, 200 ×); c neointimal area; d medial area; e arterial perimeter; f intima to media (I/M) ratio; g representative images of injured arteries showing Ki-67 immunostaining (200 ×); h, i percentage of Ki-67-positive cells to total cells in the neointima and media, respectively. The averages of three serial cross-sections were used as single data points. Arrows indicate the neointima, and arrowheads indicate Ki-67-positive cells; d–f: n = 6 for vehicle and full treatment; n = 9 for early short treatment; n = 8 for delayed treatment; i, j: n = 5 per group; *p < 0.05CC BY · PubMed Central
Fig. 5 Liraglutide stimulated NO production via the cAMP/PKA/AMPK/eNOS pathway in HUVECs. NO production by HUVECs was determined by measuring levels of the stable metabolites of NO (NO2 and NO3) in the culture medium. HUVECs were stimulated with the indicated concentrations of agents (saline or liraglutide 0.1–100 nmol/L) for 2 h, following serum starvation in M199, 0.3% FBS, for 1 h. Inhibitors were added 30 min prior to stimulation at the following concentrations: GLP-1R antagonist exendin-(9–39) (Ex-9), 100 nmol/L; cAMP inhibitor SQ22536 (SQ), 100 μmol/L; cAMP-dependent protein kinase (PKA) inhibitor fragment 14–22 myristoylated trifluoroacetate salt (PKI[14–22]), 1 μmol/L; exchange factor directly activated by cAMP inhibitor (ESI-09), 6.4 μmol/L; calcium-calmodulin-dependent protein kinase kinase inhibitor (STO-609), 10 μmol/L; AMP-activated protein kinase (AMPK) inhibitor (dorsomorphine), 10 μmol/L; Akt inhibitor 10-(4′-[[N-diethylamino]]butyl)-2-chlorophenoxazine (AktI X), 5 μmol/L; NOS inhibitor (l-NAME), 1 mmol/L; a effects of liraglutide and the Ex-9 GLP-1R antagonist on endothelial NO production, 2 h after stimulation; b effects of inhibitors of downstream molecules of GLP-1R on liraglutide-stimulated NO production; n = 4–6; *p < 0.05, ** < 0.01 vs. vehicle; †p < 0.05 vs. liraglutide 1 nmol/L
Fig. 5 Liraglutide stimulated NO production via the cAMP/PKA/AMPK/eNOS pathway in HUVECs. NO production by HUVECs was determined by measuring levels of the stable metabolites of NO (NO2 and NO3) in the culture medium. HUVECs were stimulated with the indicated concentrations of agents (saline or liraglutide 0.1–100 nmol/L) for 2 h, following serum starvation in M199, 0.3% FBS, for 1 h. Inhibitors were added 30 min prior to stimulation at the following concentrations: GLP-1R antagonist exendin-(9–39) (Ex-9), 100 nmol/L; cAMP inhibitor SQ22536 (SQ), 100 μmol/L; cAMP-dependent protein kinase (PKA) inhibitor fragment 14–22 myristoylated trifluoroacetate salt (PKI[14–22]), 1 μmol/L; exchange factor directly activated by cAMP inhibitor (ESI-09), 6.4 μmol/L; calcium-calmodulin-dependent protein kinase kinase inhibitor (STO-609), 10 μmol/L; AMP-activated protein kinase (AMPK) inhibitor (dorsomorphine), 10 μmol/L; Akt inhibitor 10-(4′-[[N-diethylamino]]butyl)-2-chlorophenoxazine (AktI X), 5 μmol/L; NOS inhibitor (l-NAME), 1 mmol/L; a effects of liraglutide and the Ex-9 GLP-1R antagonist on endothelial NO production, 2 h after stimulation; b effects of inhibitors of downstream molecules of GLP-1R on liraglutide-stimulated NO production; n = 4–6; *p < 0.05, ** < 0.01 vs. vehicle; †p < 0.05 vs. liraglutide 1 nmol/LCC BY · PubMed Central
Fig. 6 Liver kinase B1 (LKB1) is essential for liraglutide-stimulated NO production in HUVECs. HUVECs were serum-starved with EBM-2 (0.1% FBS and growth factor-free) for 6 h, and proteins were extracted after stimulation with liraglutide (10 nmol/L) for the indicated time; a representative western blot images of phosphorylated (p-) and total (t-) LKB1, AMPK, and endothelial NOS (eNOS) at 0, 5, 10, and 20 min; b–d ratio of p- to t-LKB1, AMPK, and eNOS 20 min after liraglutide stimulation, n = 4–6; *p < 0.05, **p < 0.01 vs. 0 min. Predesigned siRNAs for negative control or LKB1 were transfected to HUVECs at 25 nmol/L. HUVECs were used for experiments 72 h post-transfection; e, f representative western blot images of LKB1 and β-actin 72 h after siRNA transfection, and ratio of LKB1 to β-actin, n = 4; †p < 0.05; g effects of LKB1 knockdown on liraglutide-stimulated NO production; h–j representative western blot images of siRNA-transfected HUVECs 20 min after liraglutide stimulation, and ratio of p- to t-AMPK and eNOS, n = 5–6; †p < 0.05
Fig. 6 Liver kinase B1 (LKB1) is essential for liraglutide-stimulated NO production in HUVECs. HUVECs were serum-starved with EBM-2 (0.1% FBS and growth factor-free) for 6 h, and proteins were extracted after stimulation with liraglutide (10 nmol/L) for the indicated time; a representative western blot images of phosphorylated (p-) and total (t-) LKB1, AMPK, and endothelial NOS (eNOS) at 0, 5, 10, and 20 min; b–d ratio of p- to t-LKB1, AMPK, and eNOS 20 min after liraglutide stimulation, n = 4–6; *p < 0.05, **p < 0.01 vs. 0 min. Predesigned siRNAs for negative control or LKB1 were transfected to HUVECs at 25 nmol/L. HUVECs were used for experiments 72 h post-transfection; e, f representative western blot images of LKB1 and β-actin 72 h after siRNA transfection, and ratio of LKB1 to β-actin, n = 4; †p < 0.05; g effects of LKB1 knockdown on liraglutide-stimulated NO production; h–j representative western blot images of siRNA-transfected HUVECs 20 min after liraglutide stimulation, and ratio of p- to t-AMPK and eNOS, n = 5–6; †p < 0.05CC BY · PubMed Central
Fig. 7 The anti-restenotic effects of liraglutide are preserved in severely hyperglycemic db/db mice. db/db mice with severe hyperglycemia (random plasma glucose levels > 300 mg/dL) were treated with vehicle or liraglutide (17 nmol/kg/day), and subject to femoral artery wire injury. Changes in morphometry and cell proliferation were evaluated 26 days after injury; a vascular expression of glucagon like peptide-1 receptor (Glp-1r) in wild-type and db/db mice at the time of treatment initiation. Gene expression was assessed by real-time reverse transcription-polymerase chain reaction (RT-PCR) at the time of treatment initiation; b representative images of cross-sections of femoral arteries (EVG, 200 ×); c neointimal area; d medial area; e arterial perimeter; f intima to media (I/M) ratio; g representative images of injured arteries with Ki-67 immunostaining (200 ×); h, i percentage of Ki-67-positive cells to total cells in the neointimal and medial regions; j, k cell density in the neointima and media. The averages of three serial cross-sections were used as single data points. Arrows indicate the neointima, and arrowheads indicate Ki-67-positive cells, n = 6 per group; *p < 0.05; **p < 0.01
Fig. 7 The anti-restenotic effects of liraglutide are preserved in severely hyperglycemic db/db mice. db/db mice with severe hyperglycemia (random plasma glucose levels > 300 mg/dL) were treated with vehicle or liraglutide (17 nmol/kg/day), and subject to femoral artery wire injury. Changes in morphometry and cell proliferation were evaluated 26 days after injury; a vascular expression of glucagon like peptide-1 receptor (Glp-1r) in wild-type and db/db mice at the time of treatment initiation. Gene expression was assessed by real-time reverse transcription-polymerase chain reaction (RT-PCR) at the time of treatment initiation; b representative images of cross-sections of femoral arteries (EVG, 200 ×); c neointimal area; d medial area; e arterial perimeter; f intima to media (I/M) ratio; g representative images of injured arteries with Ki-67 immunostaining (200 ×); h, i percentage of Ki-67-positive cells to total cells in the neointimal and medial regions; j, k cell density in the neointima and media. The averages of three serial cross-sections were used as single data points. Arrows indicate the neointima, and arrowheads indicate Ki-67-positive cells, n = 6 per group; *p < 0.05; **p < 0.01CC BY · PubMed Central
Fig. 8 Effects of liraglutide on NO production under hyperglycemic conditions. HUVECs were cultured in normal (5.5 mmol/L) or high-glucose (25 mmol/L) medium 48 h prior to the experiments; a NO production 2 h after vehicle or liraglutide (10 nmol/L) stimulation under normal or high glucose conditions, n = 4–6; b representative western blot images of HUVECs cultured in high-glucose, stimulated with vehicle or liraglutide (10 nmol/L) for 20 min, and the ratio of p- to t-LKB1 (c), AMPK (d), and eNOS (e), n = 6–8; *p < 0.05; **p < 0.01
Fig. 8 Effects of liraglutide on NO production under hyperglycemic conditions. HUVECs were cultured in normal (5.5 mmol/L) or high-glucose (25 mmol/L) medium 48 h prior to the experiments; a NO production 2 h after vehicle or liraglutide (10 nmol/L) stimulation under normal or high glucose conditions, n = 4–6; b representative western blot images of HUVECs cultured in high-glucose, stimulated with vehicle or liraglutide (10 nmol/L) for 20 min, and the ratio of p- to t-LKB1 (c), AMPK (d), and eNOS (e), n = 6–8; *p < 0.05; **p < 0.01CC BY · PubMed Central
Fig. 9 Liraglutide suppressed the hyperglycemia-enhanced vascular expression of pro-inflammatory cytokines and growth factors after arterial injury. Uninjured and injured femoral arteries of wild-type and db/db mice were collected 7 days after wire injury. Gene expression was assessed by real-time RT-PCR; a–e vascular expression of Il-1, Il-6, Mcp-1, Tnf-α, and Tgf-β. Data represent the relative expression levels of target genes normalized to that of 18S rRNA, n = 6–8 per group; *p < 0.05, **p < 0.01 vs. uninjured artery; †p < 0.05, ††p < 0.01 vs. vehicle; Il, interleukin; Mcp-1, monocyte chemotactic protein; Tnf, tumor necrosis factor; Tgf, transforming growth factor
Fig. 9 Liraglutide suppressed the hyperglycemia-enhanced vascular expression of pro-inflammatory cytokines and growth factors after arterial injury. Uninjured and injured femoral arteries of wild-type and db/db mice were collected 7 days after wire injury. Gene expression was assessed by real-time RT-PCR; a–e vascular expression of Il-1, Il-6, Mcp-1, Tnf-α, and Tgf-β. Data represent the relative expression levels of target genes normalized to that of 18S rRNA, n = 6–8 per group; *p < 0.05, **p < 0.01 vs. uninjured artery; †p < 0.05, ††p < 0.01 vs. vehicle; Il, interleukin; Mcp-1, monocyte chemotactic protein; Tnf, tumor necrosis factor; Tgf, transforming growth factorCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 50

Metadata

Authors
Kushima, H., Mori, Y., Koshibu, M., Hiromura, M., Kohashi, K., Terasaki, M., Fukui, T., & Hirano, T.
Affiliations
SHOWA Medical University (JP)
Corresponding author
  • Mori, Yusaku
  • Hirano, Tsutomu
Venue
Cardiovascular Diabetology
Published
2017-10-02
Volume
16
Issue
1
Pages
122-122
ISSN
1475-2840 (ISSN-L)
OpenAlex
W2760658785
Cited by
48
References
59
Citations by year
2026: 6 · 2024: 2 · 2023: 2 · 2022: 7 · 2021: 7 · 2020: 6 · 2019: 13 · 2018: 4 · 2017: 1
FWCI
4.85
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Mitsubishi Tanabe Pharma Co.
  • MSD KK
  • Novartis Pharma KK
  • Novo Nordisk Pharma Ltd.
  • Sanwa Kagaku Kenkyusho Co., LTD.
  • Kowa Co., LTD.
  • Eli Lilly Japan KK
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
endothelial nitric oxide, arterial restenosis, intimal hyperplasia, GLP-1 receptor agonists, vascular endothelial cells, AMPK, cAMP signaling, hyperglycemia, db/db mice, wire injury, vascular inflammation, angioplasty complications, nitric oxide synthase inhibition
MeSH terms
Liraglutide, Animals, Cells, Cultured, Disease Models, Animal, Dose-Response Relationship, Drug, Humans, Hypoglycemic Agents, Male, Mice, Inbred C57BL, Mice, Obese, Nitric Oxide, Treatment Outcome, Coronary Restenosis, Mice, Human Umbilical Vein Endothelial Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis. https://app.cochat.ai/papers/10.1186/s12933-017-0603-x
The paper
Kushima, H., Mori, Y., Koshibu, M., Hiromura, M., Kohashi, K., Terasaki, M., Fukui, T., & Hirano, T. (2017). The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-017-0603-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.